Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | PTGIR | P43119 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428103 | 0.90 | PTGDR2 (0.43) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3366429 | 0.90 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL16501901 | 0.90 | SHMT1 (0.37) | PTGDR2POLB | |
| SCHEMBL13428433 | 0.85 | PTGDR2 (0.55) | PTGDR2 | |
| SCHEMBL16501906 | 0.85 | CETP (0.40) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3369749 | 0.82 | PTGDR2 (0.46) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3365386 | 0.82 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL16501903 | 0.81 | SHMT1 (0.40) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3368014 | 0.80 | POLB (0.43) | PTGDR2CYP2C9POLBDHFRSCN9A | |
| SCHEMBL1922384 | 0.79 | PTGDR2 (0.44) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.